Japan’s contract drug rep ratio rose to 8.7% in FY2024 as the total number of regular reps continued to fall, the Japan Contract Sales Organization Association (JCSOA) reported in June. Amid industry downsizing, the roles and expectations placed on contract…
Japan to Apply Leqembi’s General Pricing Rules for Similar AD Therapies
To read the full story
Related Article
- Leqembi Likely to Face 15% Price Cut Under Special CEA Rule
July 10, 2025
- Kisunla Gets Reimbursement Listing with Daily NHI Price of 8,560 Yen
November 14, 2024
- Kisunla to Follow Same Rules as Leqembi in Pricing and Post-Launch Review
October 10, 2024
- Kisunla Subject to Prior Pricing Review as It Follows Leqembi’s Footsteps
September 26, 2024
- Japan Approves Lilly’s Kisunla, Eisai’s ALS Med, Gilead’s Trodelvy, and Lots More
September 25, 2024
- Leqembi to Cost 2.98 Million Yen per Year, Re-Pricing Might Be Triggered on Patient Upswing
December 14, 2023
- Chuikyo Agrees to Adopt Normal Rules to Price, Re-Price Leqembi
November 16, 2023
- Leqembi Subject to Cost Control Rule for Potential Big Sellers, MHLW Still Set to Meet Listing Deadline
September 26, 2023
REGULATORY
- Novartis’ Radioligand Therapy, Other New Meds Up for Japan Panel Review on Aug. 22
August 12, 2025
- Japan Nears Approval for 1st Biosimilars of Actemra, Simponi, and Ranmark
August 12, 2025
- Japan Approves FY2026 Budget Guidelines, Natural Increase at 400 Billion Yen
August 12, 2025
- PMDA Flags New Potential Risks for RAS Agents and Others
August 12, 2025
- Japan Approves MSD’s 21-Valent Pneumococcal Vaccine
August 8, 2025
A recent conversation with a US biopharma senior director highlighted a critical talent gap: a strong demand for individuals with strategic management, critical thinking, and advanced business acumen-skills beyond traditional operational excellence. After the conversation, I rushed home and picked…
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
The Ministry of Health, Labor and Welfare (MHLW) posted the final report compiled by its pharmaceutical regulation panel on its website on April 24, providing cases of drugs that could be exempted from all-case post marketing surveillance (PMS).The MHLW plans…